Skip to main content
. 2019 Nov 22;14(11):e0225585. doi: 10.1371/journal.pone.0225585

Table 1. Sociodemographic and medical information of patients participated in the study of adverse drug effects of standard triple therapy in selected healthcare institutions at Bahir Dar City Administration, May 2016 to April 2018.

(N = 421).

Variable and their categories Frequency and percentage Self-report on ADEs Self-reported ADEs in %
Yes (n = 110) No (n = 311)
Sex        
Female 276(65.6) 80 196 29.0
Male 145(34.4) 30 115 20.7
Body mass index        
<20 151(35.9) 35 116 23.2
20–25 222(52.7) 56 166 25.2
>25 48(11.4) 19 29 39.6
Age in years        
18–24 125(29.7) 33 92 26.4
25–34 172(40.9) 40 132 23.3
35–44 75(17.8) 23 52 30.7
≥ 45 49(11.6) 14 35 28.6
Residence        
Urban 336(79.8) 95 241 28.3
Rural 85(20.2) 15 70 17.5
Patents' Zonal address        
Bahir Dar city 169(40.1) 45 124 26.6
West Gojjam 96(22.8) 22 74 22.9
South Gondar 62(14.7) 15 47 24.2
Awi zone 52(12.4) 16 36 30.1
Others zones 42(10.0) 12 30 28.6
Marital status        
Single 145(34.5) 34 111 23.4
Married 267(63.4) 73 194 27.3
Divorced/Widowed 9(2.1) 3 6 33.3
Occupation        
Employee 159 (37.8) 46 113 28.9
Non-employee 262(62.2) 64 198 24.4
Educational status        
Grade 1–8 and below 141(33.5) 35 106 24.8
Grade 9–12 104(24.7) 30 74 28.8
College and above 176(41.8) 45 131 25.6
Time duration of the disorder        
≤ 3weeks 110(15.9) 9 101 8.2
>3weeks 354(84.1) 101 253 28.5
Presence of other disease(s)        
Yes 108(25.6) 25 83 23.1
No 313(74.3) 85 228 27.2
Self-reported alcohol intake        
Yes 237(56.3) 52 185 21.9
No 184(43.7) 58 126 31.5
Pain feeling period in the day        
After meal 217(51.5) 46 171 21.2
Persistent in the day 122(29.0) 35 87 28.7
Long interval b/n meals 82(19.5) 29 53 35.4
Use of Flaxseed or Fenugreek        
Yes 135(32.1) 35 100 25.9
No 286(67.9) 75 211 26.2
Triple therapy regimen durations        
10 day 279(66.3) 79 200 28.3
14 day 142(33.7) 31 111 21.8
Self-reported regimen completion        
Yes 397(94.3) 100 297 25.2
No 24(5.7) 10 14 41.7
Disease symptom resolution        
Yes 355(84.3) 91 264 25.6
No 66(15.7) 19 47 28.8